## **ForPatients**

by Roche

## **Healthy Volunteers**

## A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT03222310 GP30057

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

## Trial Summary:

This study will be a single center, open-label, 2-period, fixed-sequence, Phase 1 drug-drug interaction study in healthy subjects. The primary purpose of this study is to evaluate the effect of itraconazole on the PK of ipatasertib and its primary metabolite (G-037720).

Hoffmann-La Roche Sponsor	Phase 1 Phase	
NCT03222310 GP30057 Trial Identifiers		
Eligibility Criteria:		
Gender All	Age >= 18 Years & <= 55 Years	Healthy Volunteers Accepts Healthy Volunteers